---
title: "Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292199195.md"
description: "Fate Therapeutics received FDA IND clearance for FT839, an off-the-shelf dual-target CAR T-cell therapy designed for autoimmune diseases. The company plans to begin enrollment in a Phase 1/2 basket trial in the second half of 2026."
datetime: "2026-07-09T12:33:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292199195.md)
  - [en](https://longbridge.com/en/news/292199195.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292199195.md)
generator: "portal-rs"
---

# Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839

-   FDA cleared Fate Therapeutics’ IND for FT839, an off-the-shelf dual-target CAR T-cell therapy aimed at autoimmune disease. \* Phase 1⁄2 basket trial enrollment is expected to start in H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090830PRIMZONEFULLFEED9759511) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026](https://longbridge.com/en/news/298445782.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S](https://longbridge.com/en/news/298774302.md)
- [NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects](https://longbridge.com/en/news/298966653.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**